These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27469341)

  • 1. Targeting ADAM17 Sheddase Activity in Cancer.
    Rossello A; Nuti E; Ferrini S; Fabbi M
    Curr Drug Targets; 2016; 17(16):1908-1927. PubMed ID: 27469341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution.
    Calligaris M; Cuffaro D; Bonelli S; Spanò DP; Rossello A; Nuti E; Scilabra SD
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33579029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.
    Ye J; Yuen SM; Murphy G; Xie R; Kwok HF
    Eur J Pharm Sci; 2017 Dec; 110():62-69. PubMed ID: 28554668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF‑7 cells in vitro and in vivo and its mechanism of action.
    Hu B; Meng X; Zhang Y; Hossain MM; Wu L; Zhang Y; Peng X; Zhang X
    Oncol Rep; 2018 Apr; 39(4):1640-1648. PubMed ID: 29393483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells.
    Kim TW; Ryu HH; Li SY; Li CH; Lim SH; Jang WY; Jung S
    J Neurosurg; 2017 Jun; 126(6):1829-1838. PubMed ID: 27540907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metalloprotease ADAM17 in inflammation and cancer.
    Düsterhöft S; Lokau J; Garbers C
    Pathol Res Pract; 2019 Jun; 215(6):152410. PubMed ID: 30992230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TACE: a new target in epidermal growth factor receptor dependent tumors.
    Kenny PA
    Differentiation; 2007 Nov; 75(9):800-8. PubMed ID: 17608729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor as a target for anti-cancer agent design.
    Cao J; Fang H; Wang B; Ma C; Xu W
    Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.
    Moss ML; Minond D
    Mediators Inflamm; 2017; 2017():9673537. PubMed ID: 29230082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial Cell-Derived a Disintegrin and Metalloproteinase-17 Confers Resistance to Colonic Inflammation Through EGFR Activation.
    Shimoda M; Horiuchi K; Sasaki A; Tsukamoto T; Okabayashi K; Hasegawa H; Kitagawa Y; Okada Y
    EBioMedicine; 2016 Mar; 5():114-24. PubMed ID: 27077118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells.
    Rosso O; Piazza T; Bongarzone I; Rossello A; Mezzanzanica D; Canevari S; Orengo AM; Puppo A; Ferrini S; Fabbi M
    Mol Cancer Res; 2007 Dec; 5(12):1246-53. PubMed ID: 18171982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer.
    Kenny PA
    Expert Opin Ther Targets; 2007 Oct; 11(10):1287-98. PubMed ID: 17907959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAM17, shedding, TACE as therapeutic targets.
    Rose-John S
    Pharmacol Res; 2013 May; 71():19-22. PubMed ID: 23415892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
    Janmaat ML; Giaccone G
    Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling.
    Li X; Maretzky T; Weskamp G; Monette S; Qing X; Issuree PD; Crawford HC; McIlwain DR; Mak TW; Salmon JE; Blobel CP
    Proc Natl Acad Sci U S A; 2015 May; 112(19):6080-5. PubMed ID: 25918388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term TNFα shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17.
    Schwarz J; Broder C; Helmstetter A; Schmidt S; Yan I; Müller M; Schmidt-Arras D; Becker-Pauly C; Koch-Nolte F; Mittrücker HW; Rabe B; Rose-John S; Chalaris A
    Biochim Biophys Acta; 2013 Dec; 1833(12):3355-3367. PubMed ID: 24135057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.
    Wahl O; Oswald M; Tretzel L; Herres E; Arend J; Efferth T
    Curr Med Chem; 2011; 18(21):3136-55. PubMed ID: 21671856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.